Ligand pharmaceuticals incorporated (LGND)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Total revenues

33,161

27,003

24,808

24,987

43,484

59,590

45,663

90,043

56,157

50,465

33,375

27,995

29,267

38,185

21,619

19,521

29,648

21,193

17,701

18,418

14,602

22,999

14,973

10,608

15,958

14,737

13,005

9,580

11,651

13,635

6,375

5,742

5,636

12,937

5,741

7,463

3,896

7,802

5,838

Operating costs and expenses:
Cost of Captisol

4,683

1,937

3,147

2,405

3,858

2,955

1,460

1,134

788

1,737

2,385

903

341

2,897

999

720

955

883

1,250

2,600

1,074

4,003

1,496

1,186

2,451

1,317

2,538

1,214

663

2,328

683

435

155

2,058

703

1,623

525

-

0

Amortization of intangibles

3,535

6,304

3,552

3,505

3,503

3,484

5,725

3,305

3,278

3,993

2,706

2,706

2,715

2,732

2,706

2,681

2,524

594

593

594

594

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

11,891

18,664

13,742

12,213

11,289

8,838

5,483

6,135

7,407

8,633

4,759

4,822

8,673

6,405

5,898

4,914

4,004

2,276

1,945

3,416

3,368

906

3,021

2,689

3,131

2,373

2,414

2,022

2,465

2,476

2,647

2,850

2,817

2,597

2,471

3,237

1,986

4,935

6,602

General and administrative

9,264

10,277

9,525

10,994

11,088

11,164

9,633

9,294

7,643

7,750

7,032

6,549

7,322

6,797

6,550

7,237

7,069

7,208

4,971

7,225

5,994

5,517

6,742

5,239

5,072

4,420

4,756

4,306

4,502

4,202

4,306

3,858

3,416

3,321

3,962

3,855

3,445

3,074

3,290

Lease exit and termination costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

345

218

223

562

182

136

204

200

227

44

89

357

164

414

87

721

-2

-16

-151

15,894

0

Write-off of acquired IPR&D

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

480

-

-

0

0

-

-

2,282

-

-

-

-

Total operating costs and expenses

29,373

37,182

29,966

29,117

29,738

26,441

22,301

19,868

19,116

22,113

16,882

14,980

19,051

18,831

16,153

15,552

14,552

10,175

9,104

14,053

11,253

13,363

11,441

9,250

10,858

8,310

9,935

8,066

7,719

9,363

7,800

7,557

6,475

8,697

9,416

8,699

5,805

23,903

9,892

Gain from sale of Promacta license

0

0

0

0

812,797

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of deferred gain on sale leaseback

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

424

426

426

426

426

426

Income from operations

3,788

-10,179

-5,158

-4,130

826,543

33,149

23,362

70,175

37,041

28,352

16,493

13,015

10,216

19,354

5,466

3,969

15,096

11,018

8,597

4,365

3,349

9,636

3,532

1,358

5,100

6,427

3,070

1,514

3,932

4,272

-1,425

-1,815

-839

4,664

-3,249

-810

-1,483

-15,675

-3,628

Other income (expense):
Increase in contingent liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-140

-

-958

-332

-1,306

-37

2,301

-7,274

-3

-255

-1,620

-1,312

-1,948

-3,965

-532

2,741

-1,841

-2,841

2,093

-1,415

513

302

-198

1,171

-2,288

2,460

3,690

Gain (loss) from Viking

-25,457

8,480

-10,520

-12,365

17,293

-73,271

62,398

39,963

21,097

1,454

-1,019

-1,400

-1,083

-8,993

-1,396

-11,138

-1,605

-2,104

-2,169

-870

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

4,730

5,840

7,396

9,285

5,909

4,888

5,474

2,762

875

-

564

481

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

37

59

118

Interest expense

8,548

8,834

8,993

9,012

8,906

20,142

11,200

13,454

3,480

3,792

3,386

3,341

2,941

3,670

3,116

3,051

3,005

-20,674

2,930

2,969

2,973

-6,805

1,516

181

248

-3,836

394

453

912

-5,122

735

762

701

-4,093

699

674

423

8

13

Gain on deconsolidation of Viking

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

28,190

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense, net

-4,928

-3,482

-2,596

-1,806

1,874

-1,411

-808

-3,867

-221

3,498

-581

-455

141

-2,722

1,215

501

391

-120

1,485

850

-447

544

505

1,376

-754

-137

-119

2

191

245

15

2

254

560

-10

32

48

1,728

168

Total other income (loss), net

-34,203

2,004

-14,713

-13,898

16,170

-89,936

55,864

25,404

18,271

2,315

-4,422

-4,715

-4,023

-12,125

-4,255

-14,020

-5,525

-5,191

-1,313

17,927

-3,423

-2,626

-2,631

-117

-2,950

-4,420

-1,045

2,290

-2,562

-3,322

1,373

-2,175

66

324

-907

529

-2,626

4,239

3,963

Income (loss) before income taxes

-30,415

-8,175

-19,871

-18,028

842,713

-56,787

79,226

95,579

55,312

30,667

12,071

8,300

6,193

7,229

1,211

-10,051

9,571

5,827

7,284

22,292

-74

7,010

901

1,241

2,150

2,007

2,025

3,804

1,370

950

-52

-3,990

-773

4,988

-4,156

-281

-4,109

-11,436

335

Income tax benefit (expense)

-6,284

-810

-4,620

-3,609

176,376

-14,307

11,864

22,419

10,033

37,674

3,645

2,242

1,114

10,354

160

-3,881

3,694

-514

-191,881

265

15

280

124

-47

53

138

60

110

66

-1,636

142

338

-35

297

22

141

-13,730

419

625

Income (loss) from operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,125

1,051

-6,170

5,877

6,341

199,165

22,027

-89

-

-

-

2,097

-

1,965

3,694

-

-

-

-

-

-

-

-

-

-

-

Discontinued operations:
Net income from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,304

2,586

-194

-4,328

-738

4,691

-4,178

-422

9,621

-11,855

-290

Gain on sale of Oncology Product Line before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,139

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax expense on discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-8

0

0

408

0

0

0

0

-

-

-

-

-

-

-

-

1,523

0

-191

177

-

0

0

-

-

-

Income from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,397

191

0

0

1,608

2,048

-

-

-

-

-

-

Income from discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

731

-

0

0

0

-

-

-

-

-

0

2,397

191

-1,523

0

1,799

1,871

-1

0

0

4

12

7

Net income (loss) including noncontrolling interests

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,341

199,165

22,027

-89

6,730

777

1,288

2,097

-

1,965

6,091

-

-

-

-

-

-

-

-

-

-

-

Less: Net loss attributable to noncontrolling interests

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,760

0

-1,537

-843

-325

-503

-304

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Net income (loss)

-24,131

-7,365

-15,251

-14,419

666,337

-42,480

67,362

73,160

45,279

-7,007

8,426

6,058

5,079

-3,125

1,051

-6,170

6,608

6,341

199,165

23,564

754

7,055

1,280

1,592

2,097

1,869

1,965

6,091

1,495

1,063

-194

-2,529

1,133

4,690

-4,178

-422

9,625

-11,843

-283

Earnings Per Share [Abstract]
Earnings Per Share, Basic and Diluted:
Income (loss) from continuing operations (USD per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.14

0.05

-0.30

0.28

0.37

10.01

1.19

0.04

-

-

-

-

0.09

0.10

0.18

0.06

0.13

-0.01

-0.22

-0.04

0.23

-0.21

-0.02

0.49

-0.60

-0.01

Income from discontinued operations (USD per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

0.00

0.00

0.04

0.00

0.00

0.00

0.00

-

-

-

-

0.00

0.00

0.12

0.01

-

0.00

0.09

-

-

-

-

-

-

-

Basic net income (loss) per share (USD per share)

-1.46

2.09

-0.81

-0.74

32.59

-2.00

3.19

3.45

2.13

-0.33

0.40

0.29

0.24

-0.15

0.05

-0.30

0.32

0.37

10.01

1.19

0.04

-

0.06

0.08

-

0.09

0.10

0.30

0.07

-

-0.01

-0.13

-

-

-

-

-

-

-

Weighted average common shares outstanding:
Discontinued operations (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

0.00

0.00

-

-

0.00

Basic and diluted net income per share (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

-

-

-

-

-

-

0.06

-

-0.21

-0.02

0.49

-0.60

-0.01

Shares used in basic per share calculations (shares)

16,529

17,205

18,770

19,558

20,447

21,071

21,148

21,212

21,209

21,106

21,071

21,013

20,938

20,897

20,887

20,832

20,708

19,936

19,887

19,725

19,612

19,919

20,417

20,738

20,600

20,444

20,357

20,258

20,189

20,036

19,917

19,749

19,709

-

19,673

19,650

-

19,629

19,608

Diluted per share amounts:
Income (loss) from continuing operations (USD per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.12

0.05

-0.30

0.26

0.40

9.28

1.11

0.04

-

-

-

-

0.10

0.09

0.18

0.06

-

-0.01

-0.22

-

-

-

-

-

-

-

Income from discontinued operations (USD per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

0.01

0.00

0.00

0.03

0.00

0.00

0.00

0.00

-

-

-

-

-0.01

0.00

0.12

0.01

-

0.00

0.09

-

-

-

-

-

-

-

Diluted net income (loss) per share (USD per share)

-1.46

2.08

-0.81

-0.74

31.32

-1.66

2.80

2.99

1.83

-0.31

0.36

0.26

0.22

-0.13

0.05

-0.30

0.30

0.40

9.28

1.11

0.04

-

0.06

0.07

-

0.09

0.09

0.30

0.07

-

-0.01

-0.13

-

-

-

-

-

-

-

Shares used in diluted per share calculations (shares)

16,529

19,423

18,770

19,558

21,277

22,978

24,052

24,438

24,800

24,137

23,551

23,215

23,019

17,210

22,997

20,831

22,283

21,545

21,459

21,276

20,630

21,398

21,345

21,780

21,208

21,430

20,843

20,427

20,280

20,006

19,917

19,749

19,738

19,906

19,673

19,650

19,623

19,629

19,608

Royalties
Total revenues

6,565

11,045

9,767

6,626

19,538

40,213

36,127

31,396

20,820

28,313

21,931

14,211

24,230

19,581

15,698

9,754

14,390

11,546

9,755

6,606

10,287

9,421

7,482

5,241

7,850

7,118

5,724

4,916

5,826

4,817

3,213

2,983

3,060

2,617

2,431

2,172

1,993

1,774

1,601

Captisol
Total revenues

21,109

7,132

6,849

8,549

8,959

10,093

7,027

7,612

4,391

7,735

7,664

5,550

1,121

9,056

4,219

3,886

5,341

7,206

6,046

10,681

3,729

12,963

6,334

3,476

5,715

6,812

6,728

3,993

1,539

5,282

1,818

1,665

667

6,441

1,679

2,984

1,019

-

0

Service revenue
Total revenues

3,357

-

-

-

3,883

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue
Total revenues

2,130

-

-

-

11,104

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License fees, milestones and other revenues
Total revenues

-

-

8,192

9,812

-

9,284

2,509

51,035

30,946

14,417

3,780

8,234

3,916

9,548

1,702

5,881

9,917

2,441

1,900

1,131

586

615

1,157

1,891

2,393

807

553

671

4,286

3,536

1,344

1,094

1,909

3,879

1,631

2,307

884

6,028

4,237